← Back to Clinical Trials
Recruiting NCT07093177

NCT07093177 Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07093177
Status Recruiting
Phase
Sponsor University of Utah
Condition Prostate Cancer
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-02-24
Primary Completion 2028-09

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Telerehabilitation Unit

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-02-24 with a primary completion date of 2028-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Prostate cancer has a significant impact on patient quality of life (QoL) directly, as well as through the management of localized disease (such as surgery and radiation-related incontinence, erectile dysfunction, and bowel dysfunction), and via direct side effects of androgen deprivation therapy (ADT) resulting in a considerable physical and psychological burden. Recent studies demonstrated the efficacy of multimodal rehabilitation for functional recovery, improvements in QoL, reduction in cancer symptoms, and secondary and tertiary prevention. Despite the mounting evidence regarding the benefits of multimodal rehabilitation for this population, multiple barriers limit the access of prostate cancer survivors to cancer rehabilitation, especially in rural areas. This study is a pilot study to assess usability, acceptability, and exercise adherence in 12-week multimodal telerehabilitation in patients receiving ADT with either high-risk or metastatic prostate cancer residing in rural areas.

Eligibility Criteria

Inclusion Criteria: * Age 18 and older * Confirmed diagnosis of prostate cancer * Men receiving standard-of-care ADT either for high-risk, locally advanced prostate cancer or as a part of multicomponent management of metastatic prostate cancer * Residing in a rural community, as indicated by zip code in RUCA areas Exclusion Criteria: * Unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures * Engaged in a regular exercise rehabilitation program * Relocation plans within next 3 months * Participating in another clinical trial * Have a working telephone line in their home or a cell phone.

Contact & Investigator

Central Contact

Manish Kohli, MD

✉ Manish.Kohli@hci.utah.edu

📞 801-646-4018

Principal Investigator

Manish Kohli, MD

PRINCIPAL INVESTIGATOR

Huntsman Cancer Institute

Frequently Asked Questions

Who can join the NCT07093177 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07093177 currently recruiting?

Yes, NCT07093177 is actively recruiting participants. Contact the research team at Manish.Kohli@hci.utah.edu for enrollment information.

Where is the NCT07093177 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT07093177 clinical trial?

NCT07093177 is sponsored by University of Utah. The principal investigator is Manish Kohli, MD at Huntsman Cancer Institute. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology